Antibody Drug Conjugates Contract Market
Antibody Drug Conjugates Contract Market Analysis By Condition Type (Myeloma, Lymphoma, Breast Cancer, Other Condition Types), By Application Type (Cleavable Linker, Non-cleavable Linker), and By Region - Global Market Insights 2022 to 2032
Analysis of Antibody Drug Conjugates Contract market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Antibody Drug Conjugates Contract Market Outlook (2022-2032)
The global antibody drug conjugate contract market demand is anticipated to be valued at US$ 9.2 Billion in 2022, forecast a CAGR of 15.5% to be valued at US$ 38.8 Billion from 2022 to 2032. From 2017-2021 a CAGR of 12.7% was registered for the antibody drug conjugate contract market.
The global sales of the antibody-drug conjugates contract market in 2021 were held at US$ 8.1 Billion. The antibody-drug conjugates contract market is accounted to give an absolute dollar opportunity growth of nearly US$ 29.7 Billion during 2022-2032.
Antibody-drug conjugation (ADC) technology uses monoclonal antibodies (mAbs) to deliver potent, highly active pharmaceutical ingredients (HPAPIs) to targeted cells. In conjugated form, HPAPIs exhibit selective cytotoxicity which can spare non-target cells from toxic effects.
The antibody-drug conjugates contract market is anticipated to gain promising growth owing to the heightening prevalence of cancer around the world during the forecast period 2022-2032. As targeted therapy is needed to overcome cancer is necessary as many cancer cases generally result in fatalities.
Antibody-drug conjugate contract is complex powerful biologics that have the potential to treat a wide range of ailments, including cancer. The capacity of these therapies to successfully target disease-associated cells while limiting off-target damage is credited with their clinical potential.
According to the ADC Review, about 70% of ADC projects are outsourced to contract development and manufacturing organizations (CDMOs), and this trend is projected to continue with the pipelines' continuing expansion. As more commercial goods reach the market, CDMOs who understand how to conduct late-stage studies to support the filing strategy is in high demand.
CMOS are setting up systems to address the difficult supply chains and investing in facilities and processes to ensure security, quality, and efficiency in commercial-scale ADC manufacture. As a result of the planned growth in ADC demand, the contract manufacturing market for ADCs is expected to grow significantly in the future years.
Attributes |
Details |
|---|---|
|
Anticipated Base Year Value (2021) |
US$ 8.1 Billion |
|
Expected Market Value (2022) |
US$ 9.2 Billion |
|
Projected Forecast Value (2032) |
US$ 29.7 Billion |
|
Global Growth Rate (2022-2032) |
15.5% |
|
Market share of US (2022) |
13.7% |
|
CAGR of China (2022-2032) |
12.6% |
|
Prominent Players in The Global Market |
|
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Revenue of Antibody Drug Conjugates Contract Market from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032
As per the Antibody Drug Conjugates Contract Market industry research by Fact.MR - market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Antibody Drug Conjugates Contract Market industry increased at around 12.7% CAGR, wherein, countries such as the U.S., China, Japan, South Korea, and the UK held a significant share in the global market.
The market for Antibody Drug Conjugates Contract is expected to grow at an immense rate and show some great results in the upcoming years. The global production of antibody-drug conjugates contracts, vaccines, and other pharmaceuticals is expected to increase as a result of the increased demand for effective COVID-19 treatments.
The Antibody Drug Conjugates Contract Market reached a valuation of US$ 8.1 Billion in 2021 and is expected to cross US$ 9.2 Billion mark by the end of 2022.
Top condition type Myeloma is expected to grow with a huge CAGR of 17% during the forecasted period of 2022 to 2032.
From the top application type perspective, Cleavable Linker has shown the CAGR of 12.6% in the historical data and is expected to grow at the rate of 17.2% in the next 10 years.
From the North America region, the United States market size by the end of forecast period is anticipated to be around US$ 7.3 Billion with an absolute dollar growth of US$ 5.3 Billion.
What Market Trends Are Influencing Antibody Drug Conjugates Contract Market Sales?
Growing demand for the biological treatment to boost the antibody-drug conjugates contract market
The growing demand for manufacturing capacity as well as an increasing number of research on antibody therapies to drive the growth of the antibody-drug conjugates contract market during the forecast period.
The Antibody Drug Conjugates Contract Market is predicted to grow significantly throughout the forecast period as a result of subcontracting services and operations to contract manufacturing organizations, increased demand for biologic treatments, and rising cancer occurrences.
With time and research, scientists have enhanced the design and development procedure for these medicines. As a result, four new ADCs will be approved in 2019 and 2020. The US Food and Drug Administration has approved 12 ADCs so far, with another 100 in the works.
Growing prevalence of breast cancer to drive the market growth
The rising application of antibody drug conjugates across breast cancer is anticipated to bring vital growth to the antibody drug conjugates contract market.
Clinical trials for many antibody drug conjugates are in process and are expected to be approved shortly. Thus, this aspect may invite significant growth for the antibody drug conjugates contract market.
For instance, according to the National Cancer Institute estimates that cancer diagnosis is extrapolated to reach approximately 19 mn by 2024. Thus, these factors may bring positive growth for the antibody drug conjugates contract market through the assessment period.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Are The Current Restraining Factors For The Antibody Drug Conjugates Contract Market?
The growing complexity of the biologic business makes most drugs today made by pharmaceutical companies. This, in turn, has negatively impacted the market for contract manufacturing of antibody drug conjugates.
ADCs are a unique niche in the pharmaceutical industry, with numerous manufacturers executing almost all of the steps, resulting in a high risk of bureaucratic complications. Additionally, since there is about 70 failed clinical trials for ADCs and just a few commercialized products, there is a need to streamline the supply chain to increase productivity.
Comparative View of Addiction Treatment Markets
Antibody Drug Conjugates Contract Market :
|
Attributes |
Antibody Drug Conjugates Contract Market |
|
Growth Factor |
The global production of antibody-drug conjugates contracts, vaccines, and other pharmaceuticals is expected to increase as a result of the increased demand for effective COVID-19 treatment. |
|
Opportunity |
Increasing prevalence of cancer is expected to provide opportunities for the growth of antibody drug conjugates contract market. |
Antibody Drug Conjugates Market :
|
Attributes |
Antibody Drug Conjugates Market |
|
Growth Factor |
The rising application of antibody-drug conjugates across breast cancer is anticipated to bring vital growth to the antibody-drug conjugates market. |
|
Opportunity |
The escalating prevalence of cancer across the globe bring positive growth for the antibody drug conjugates market through the assessment period. |
Antibody Drug Market :
|
Attributes |
Antibody Drug Market |
|
Growth Factor |
The rising demand for efficient and effective immunotherapy treatment solutions is positively influencing the trajectory of the global antibody drugs market. |
|
Opportunity |
The rising application of monoclonal antibodies in the field of immunotherapy for disorders including cancer, such as oncolytic virus therapy, cancer vaccines, checkpoint inhibitors, and T cell therapy, is one of the major drivers for the development within the global antibody drugs market. |
Region-wise Insights
Will Revenue Growth Keep the Momentum High for the North America Antibody Drug Conjugates Contract Market?
Rising Usage in Healthcare Sector Bolstering Sales of the Antibody Drug Conjugates Contract Market in North America
North America dominated the market in terms of revenue in 2022. The increasing prevalence of cancer are the major factors responsible for the dominance of the region. US holds the largest share of North American market.
The US government will be driving the market of U.S. medicinal products through ADC contracts. The projected CAGR for the period from 2017 to 2021 is 13.1%, and from 2022 to 2032 is 13.7%. By 2032, the U.S. leads the market with a projected value of US$ 7.3 Bn.
The growing instances of cancer in the United States, in addition to looking for coping techniques, is raising the interest in ADCs. According to the Centers for Disease Control and Prevention (CDC), 1,708,921 new cancer cases were reported in the US in 2018, with a total of 599,265 deaths. As of May 2021, the Food and Drug Administration (FDA) has approved ten radiopharmaceuticals for treating breast cancer, bladder cancer, multiple myeloma, acute leukemia, and lymphoma.
Why is Asia Pacific Prominent Market for Antibody Drug Conjugates Contract?
Rising prevalence of cancer in the region to boost the market growth
The Asia Pacific led the antibody-drug conjugates contract manufacturing market with a 46.4 % revenue share in 2020. The Asia Pacific accounts for 48% of all new cancer cases worldwide. Out of all the cases, China holds nearly half of the sufferers.
The market for APAC antibody-drug conjugates contract is developing due to the rising frequency of cancer and the growing geriatric population. According to Globocan Data 2020, 52% of cancer patients are 65 or older, and by 2040, this number is expected to quadruple. The most frequent cancer in China is lung cancer, which is followed by stomach, liver, colon, rectum, and breast cancers.
Category-wise Insights
Why Myeloma is Gaining the Utmost Traction when compared with other Condition Types of Antibody Drug Conjugates Contract?
Myeloma is expected to be the highest revenue-generating condition type
The Myeloma segment is the top condition type segment which grew with a CAGR of 13.2% during 2017-2021 and is anticipated to bounce and grow with a CAGR of 17% in the forecasted period of 2022-2032. This is partly because antibody-drug conjugates contract is a new type of immunotherapy that is now being investigated and evaluated in the treatment of myeloma.
The target site for the monoclonal antibody is the main aggressive component of the monoclonal antibody. As a result, this kind of medication has a very variable effect on damaged cells. As a result, this therapeutic modality is more effective in treating patients suffering from multiple myeloma because it has a rapid onset and broad applicability.
How is Cleavable Linker is more promising application type segment?
Clever linker accounts for highest share of application segment
The most essential aspect affecting the section's expansion is the compensations that cleavable linkers receive in various situations to provide medicine to the object cell. The market segment for cleavable linkers grew with a CAGR of 12.6% during the historical period of 2017-2021 is expected to grow with a CAGR of 17.2% during the forecasted period of 2022-2032.
Cleavable linkers are the most commonly available kind of ADC linker. The most significant benefit of cleavable linkers is the fact that they are cleaved in response to extracellular and intracellular environments by environmental and lysosomal enzymes.
According to a paper published in April 2019 called "Analysis of key factors related to ADCs structural design," cleavable linkers were used in more than two-thirds of ADCs currently in use in clinical trials.
Start-Ups for Antibody Drug Conjugates Contract Market
The new companies that have started to deal with the various kinds of antibody-drug conjugates contracts have been focussed at employing smart technologies to enhance the productivity as well as efficiency in the field.
Some of the recent developments of Antibody Drug Conjugates Contract Market providers are as follows :
- October 20, 2022 - Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announced expansion program to increase biologics CGMP analytical capabilities. The additional capacity will increase the capabilities that Catalent has across its network in both standalone services and integrated development programs.
Competitive Landscape
The contract manufacturing industry for antibody drug conjugates is very competitive, with numerous prominent companies. Pantheon, Corden Pharma, Abbvie Inc, Novasep, Merck Lonza group, Cambrex Corporation, Recipharm, Thermo Fisher Scientific, Inc, and Sterling Pharma Solutions are some of the market leaders.
Companies are making significant efforts and capital investments to increase their skills and, as a result, enhance their respective service lineups in order to acquire a competitive advantage. Some companies have built new facilities dedicated to the production of highly powerful chemicals. Various agreements between medication inventors and ADC makers have also been observed in the field.
- In September 2020, Merck announced a EUR 59 million expansion of its ADC manufacturing capabilities at its Wisconsin site. This investment is likely to enable the large-scale production of increasingly effective chemicals for cancer therapy.
- In January 2022, Recipharm announced the purchase of GenIbet to expand its biologics platform.
- In August 2021, Recipharm announced that it has opened a new laboratory to boost its analytical services.
- In July 2021, Lonza Group has extended its relationship with a large biopharmaceutical sector client for the supply of an antibody-drug conjugate against hard-to-treat malignancies.
Market Segments Covered in Antibody Drug Conjugates Contract Market Industry Analysis
-
By Condition Type :
- Myeloma
- Lymphoma
- Breast Cancer
- Other Condition Types
-
By Application :
- Cleavable Linker
- Non-cleavable Linker
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Fact.MR Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Antibody Drug Conjugates Contract Demand 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background and Foundation Data Points 4.1. Antibody Drug Conjugates Contract Market (US$ Mn) 4.2. Antibody Drug Conjugates Contract Market Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Antibody Drug Conjugates Contract Market Growth 4.5.3. Antibody Drug Conjugates Contract Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Antibody Drug Conjugates Contract Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Antibody Drug Conjugates Contract Market Demand Analysis 2017-2021and Forecast, 2022-2032 6.1. Historical Market Analysis, 2017-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Antibody Drug Conjugates Contract Market Value Analysis 2017-2021and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032, By Condition Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Condition Type, 2017-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Condition Type, 2022-2032 8.3.1. Myeloma 8.3.2. Lymphoma 8.3.3. Breast Cancer 8.3.4. Other Condition Types 8.4. Market Attractiveness Analysis By Condition Type 9. Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032, By Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2017-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2032 9.3.1. Cleavable Linker 9.3.2. Non-cleavable Linker 9.4. Market Attractiveness Analysis By Application 10. Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032, By Region 10.1. Introduction 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021 10.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. APAC 10.3.5. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032 11.1. Introduction 11.2. Pricing Analysis 11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 11.4.1. By Country 11.4.1.1. U.S. 11.4.1.2. Canada 11.4.2. By Condition Type 11.4.3. By Application 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Condition Type 11.5.3. By Application 12. Latin America Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. Brazil 12.4.1.2. Mexico 12.4.1.3. Rest of Latin America 12.4.2. By Condition Type 12.4.3. By Application 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Condition Type 12.5.3. By Application 13. Europe Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. Germany 13.4.1.2. France 13.4.1.3. U.K. 13.4.1.4. Italy 13.4.1.5. Spain 13.4.1.6. Russia 13.4.1.7. Rest of Europe 13.4.2. By Condition Type 13.4.3. By Application 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Condition Type 13.5.3. By Application 14. Asia Pacific Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. China 14.4.1.2. Japan 14.4.1.3. India 14.4.1.4. Australia 14.4.1.5. South Korea 14.4.1.6. Rest of Asia Pacific 14.4.2. By Condition Type 14.4.3. By Application 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Condition Type 14.5.3. By Application 15. Middle East and Africa Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 15.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. Saudi Arabia 15.4.1.2. South Africa 15.4.1.3. Israel 15.4.1.4. UAE 15.4.1.5. Rest of Middle East and Africa 15.4.2. By Condition Type 15.4.3. By Application 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Condition Type 15.5.3. By Application 16. Key Countries Antibody Drug Conjugates Contract Market Analysis 2017-2021and Forecast 2022-2032 16.1. Introduction 16.1.1. Market Value Proportion Analysis, By Key Countries 16.1.2. Global Vs. Country Growth Comparison 16.2. US Antibody Drug Conjugates Contract Market Analysis 16.2.1. Value Proportion Analysis by Market Taxonomy 16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.2.2.1. By Condition Type 16.2.2.2. By Application 16.3. Canada Antibody Drug Conjugates Contract Market Analysis 16.3.1. Value Proportion Analysis by Market Taxonomy 16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.3.2.1. By Condition Type 16.3.2.2. By Application 16.4. Mexico Antibody Drug Conjugates Contract Market Analysis 16.4.1. Value Proportion Analysis by Market Taxonomy 16.4.2. Value & Analysis and Forecast by Market Taxonomy,2017-2032 16.4.2.1. By Condition Type 16.4.2.2. By Application 16.5. Brazil Antibody Drug Conjugates Contract Market Analysis 16.5.1. Value Proportion Analysis by Market Taxonomy 16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.5.2.1. By Condition Type 16.5.2.2. By Application 16.6. Germany Antibody Drug Conjugates Contract Market Analysis 16.6.1. Value Proportion Analysis by Market Taxonomy 16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.6.2.1. By Condition Type 16.6.2.2. By Application 16.7. France Antibody Drug Conjugates Contract Market Analysis 16.7.1. Value Proportion Analysis by Market Taxonomy 16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.7.2.1. By Condition Type 16.7.2.2. By Application 16.8. Italy Antibody Drug Conjugates Contract Market Analysis 16.8.1. Value Proportion Analysis by Market Taxonomy 16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.8.2.1. By Condition Type 16.8.2.2. By Application 16.9. AUSTRALIA Antibody Drug Conjugates Contract Market Analysis 16.9.1. Value Proportion Analysis by Market Taxonomy 16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.9.2.1. By Condition Type 16.9.2.2. By Application 16.10. UK Antibody Drug Conjugates Contract Market Analysis 16.10.1. Value Proportion Analysis by Market Taxonomy 16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.10.2.1. By Condition Type 16.10.2.2. By Application 16.11. INDIA Antibody Drug Conjugates Contract Market Analysis 16.11.1. Value Proportion Analysis by Market Taxonomy 16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.11.2.1. By Condition Type 16.11.2.2. By Application 16.12. China Antibody Drug Conjugates Contract Market Analysis 16.12.1. Value Proportion Analysis by Market Taxonomy 16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.12.2.1. By Condition Type 16.12.2.2. By Application 16.13. Japan Antibody Drug Conjugates Contract Market Analysis 16.13.1. Value Proportion Analysis by Market Taxonomy 16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.13.2.1. By Condition Type 16.13.2.2. By Application 16.14. South Korea Antibody Drug Conjugates Contract Market Analysis 16.14.1. Value Proportion Analysis by Market Taxonomy 16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.14.2.1. By Condition Type 16.14.2.2. By Application 16.15. ISRAEL Antibody Drug Conjugates Contract Market Analysis 16.15.1. Value Proportion Analysis by Market Taxonomy 16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.15.2.1. By Condition Type 16.15.2.2. By Application 16.16. South Africa Antibody Drug Conjugates Contract Market Analysis 16.16.1. Value Proportion Analysis by Market Taxonomy 16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.16.2.1. By Condition Type 16.16.2.2. By Application 16.17. UAE Antibody Drug Conjugates Contract Market Analysis 16.17.1. Value Proportion Analysis by Market Taxonomy 16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.17.2.1. By Condition Type 16.17.2.2. By Application 16.18. Spain Antibody Drug Conjugates Contract Market Analysis 16.18.1. Value Proportion Analysis by Market Taxonomy 16.18.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.18.2.1. By Condition Type 16.18.2.2. By Application 16.19. Russia Antibody Drug Conjugates Contract Market Analysis 16.19.1. Value Proportion Analysis by Market Taxonomy 16.19.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.19.2.1. By Condition Type 16.19.2.2. By Application 16.20. Russia Antibody Drug Conjugates Contract Market Analysis 16.20.1. Value Proportion Analysis by Market Taxonomy 16.20.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032 16.20.2.1. By Condition Type 16.20.2.2. By Application 16.20.3. Competition Landscape and Player Concentration in the Country 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Concentration 17.3. Market Share Analysis of Top Players 17.4. Market Presence Analysis 17.4.1. By Regional footprint of Players 17.4.2. Product footprint by Players 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive 18.3.1. Cambrex Corporation 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Sales Footprint 18.3.1.4. Strategy Overview 18.3.2. ReciPharm 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Sales Footprint 18.3.2.4. Strategy Overview 18.3.3. ThermoFisher 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Sales Footprint 18.3.3.4. Strategy Overview 18.3.4. Pantheon 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Sales Footprint 18.3.4.4. Strategy Overview 18.3.5. Corden Pharma 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Sales Footprint 18.3.5.4. Strategy Overview 18.3.6. Abbvie Inc. 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Sales Footprint 18.3.6.4. Strategy Overview 18.3.7. Novasep 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Sales Footprint 18.3.7.4. Strategy Overview 18.3.8. Lonza Group 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Sales Footprint 18.3.8.4. Strategy Overview 18.3.9. Thermo Fisher Scientific Inc. 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Sales Footprint 18.3.9.4. Strategy Overview 18.3.10. Sterling Pharma Solutions 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Sales Footprint 18.3.10.4. Strategy Overview 19. Assumptions and Acronyms Used 20. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2017 – 2021
Table 02: Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2022 – 2032
Table 03: Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2017 – 2021
Table 04: Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2022 – 2032
Table 05: Antibody Drug Conjugates Contract Market, By Region, 2017 – 2021
Table 06: Antibody Drug Conjugates Contract Market, By Region, 2022 – 2032
Table 07: North America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2017 – 2021
Table 08: North America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2022 – 2032
Table 09: North America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2017 – 2021
Table 10: North America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2022 – 2032
Table 11: North America Antibody Drug Conjugates Contract Market, By Country, 2017 – 2021
Table 12: North America Antibody Drug Conjugates Contract Market, By Country, 2022 – 2032
Table 13: Latin America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2017-2021
Table 14: Latin America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2022 – 2032
Table 15: Latin America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2017-2021
Table 16: Latin America Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2022 – 2032
Table 17: Latin America Antibody Drug Conjugates Contract Market, By Country, 2017-2021
Table 18: Latin America Antibody Drug Conjugates Contract Market, By Country, 2022 – 2032
Table 19: Europe Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2017-2021
Table 20: Europe Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2022 – 2032
Table 21: Europe Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2017-2021
Table 22: Europe Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2022 – 2032
Table 23: Europe Antibody Drug Conjugates Contract Market, By Country, 2017-2021
Table 24: Europe Antibody Drug Conjugates Contract Market, By Country, 2022 – 2032
Table 25: Asia Pacific Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2017-2021
Table 26: Asia Pacific Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2022 – 2032
Table 27: Asia Pacific Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2017-2021
Table 28: Asia Pacific Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2022 – 2032
Table 29: Asia Pacific Antibody Drug Conjugates Contract Market, By Country, 2017-2021
Table 30: Asia Pacific Antibody Drug Conjugates Contract Market, By Country, 2022 – 2032
Table 31: MEA Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2017-2021
Table 32: MEA Antibody Drug Conjugates Contract Market Value (US$ Mn), By Condition Type, 2022 – 2032
Table 33: MEA Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2017-2021
Table 34: MEA Antibody Drug Conjugates Contract Market Value (US$ Mn), By Application, 2022 – 2032
Table 35: MEA Antibody Drug Conjugates Contract Market, By Country, 2017-2021
Table 36: MEA Antibody Drug Conjugates Contract Market, By Country, 2022 – 2032
Table 37: Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Condition Type, 2017-2021
Table 38: Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Application, 2022 – 2032
Table 39: Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Region, 2022 – 2032
Table 40: North America Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Condition Type, 2017-2021
Table 41: North America Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Application, 2022 – 2032
Table 42: North America Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 43: Latin America Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Condition Type, 2017-2021
Table 44: Latin America Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Application, 2022 – 2032
Table 45: Latin America Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 46: Europe Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Condition Type, 2017-2021
Table 47: Europe Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Application, 2022 – 2032
Table 48: Europe Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Country, 2022 - 2032
Table 49: Asia Pacific Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Condition Type, 2017-2021
Table 50: Asia Pacific Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Application, 2022 – 2032
Table 51: Asia Pacific Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 52: MEA Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Condition Type, 2017-2021
Table 53: MEA Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Application, 2022 – 2032
Table 54: MEA Antibody Drug Conjugates Contract Market Incremental $ Opportunity, By Country, 2022 - 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Antibody Drug Conjugates Contract Market Value (US$ Mn) and Year-on-Year Growth,2017-2032
Figure 02: Antibody Drug Conjugates Contract Market Absolute $ Historical Gain (2017-2021) and Opportunity (2022 – 2032), US$ Mn
Figure 03: Antibody Drug Conjugates Contract Market Share, By Condition Type, 2022 & 2032
Figure 04: Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Condition Type – 2022-2032
Figure 05: Antibody Drug Conjugates Contract Market Attractiveness Index, By Condition Type – 2022-2032
Figure 06: Antibody Drug Conjugates Contract Market Share, By Application, 2022 & 2032
Figure 07: Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Application – 2022-2032
Figure 08: Antibody Drug Conjugates Contract Market Attractiveness Index, By Application – 2022-2032
Figure 09: Antibody Drug Conjugates Contract Market Share, By Region, 2022 & 2032
Figure 10: Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Region – 2022-2032
Figure 11: Antibody Drug Conjugates Contract Market Attractiveness Index, By Region – 2022-2032
Figure 12: North America Antibody Drug Conjugates Contract Market Value (US$ Mn) and Year-on-Year Growth,2017-2032
Figure 13: North America Antibody Drug Conjugates Contract Market Absolute $ Opportunity Historical (2017-2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 14: North America Antibody Drug Conjugates Contract Market Share, By Condition Type, 2022 & 2032
Figure 15: North America Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Condition Type – 2022-2032
Figure 16: North America Antibody Drug Conjugates Contract Market Attractiveness Index, By Condition Type – 2022-2032
Figure 17: North America Antibody Drug Conjugates Contract Market Share, By Application, 2022 & 2032
Figure 18: North America Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Application – 2022-2032
Figure 19: North America Antibody Drug Conjugates Contract Market Attractiveness Index, By Application – 2022-2032
Figure 20: North America Antibody Drug Conjugates Contract Market Share, By Country, 2022 & 2032
Figure 21: North America Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 22: North America Market Attractiveness Index, By Country – 2022-2032
Figure 23: Latin America Antibody Drug Conjugates Contract Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 24: Latin America Antibody Drug Conjugates Contract Market Absolute $ Opportunity Historical (2017-2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 25: Latin America Antibody Drug Conjugates Contract Market Share, By Condition Type, 2022 & 2032
Figure 26: Latin America Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Condition Type – 2022-2032
Figure 27: Latin America Antibody Drug Conjugates Contract Market Attractiveness Index, By Condition Type – 2022-2032
Figure 28: Latin America Antibody Drug Conjugates Contract Market Share, By Application, 2022 & 2032
Figure 29: Latin America Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Application – 2022-2032
Figure 30: Latin America Antibody Drug Conjugates Contract Market Attractiveness Index, By Application – 2022-2032
Figure 31: Latin America Antibody Drug Conjugates Contract Market Share, By Country, 2022 & 2032
Figure 32: Latin America Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 33: Latin America Antibody Drug Conjugates Contract Market Attractiveness Index, By Country – 2022-2032
Figure 34: Europe Antibody Drug Conjugates Contract Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 35: Europe Antibody Drug Conjugates Contract Market Absolute $ Opportunity Historical (2017-2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 36: Europe Antibody Drug Conjugates Contract Market Share, By Condition Type, 2022 & 2032
Figure 37: Europe Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Condition Type – 2022-2032
Figure 38: Europe Antibody Drug Conjugates Contract Market Attractiveness Index, By Condition Type – 2022-2032
Figure 39: Europe Antibody Drug Conjugates Contract Market Share, By Application, 2022 & 2032
Figure 40: Europe Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Application – 2022-2032
Figure 41: Europe Antibody Drug Conjugates Contract Market Attractiveness Index, By Application – 2022-2032
Figure 42: Europe Antibody Drug Conjugates Contract Market Share, By Country, 2022 & 2032
Figure 43: Europe Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 44: Europe Antibody Drug Conjugates Contract Market Attractiveness Index, By Country – 2022-2032
Figure 45: MEA Antibody Drug Conjugates Contract Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 46: MEA Antibody Drug Conjugates Contract Market Absolute $ Opportunity Historical (2017-2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 47: MEA Antibody Drug Conjugates Contract Market Share, By Condition Type, 2022 & 2032
Figure 48: MEA Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Condition Type – 2022-2032
Figure 49: MEA Antibody Drug Conjugates Contract Market Attractiveness Index, By Condition Type – 2022-2032
Figure 50: MEA Antibody Drug Conjugates Contract Market Share, By Application, 2022 & 2032
Figure 51: MEA Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Application – 2022-2032
Figure 52: MEA Antibody Drug Conjugates Contract Market Attractiveness Index, By Application – 2022-2032
Figure 53: MEA Antibody Drug Conjugates Contract Market Share, By Country, 2022 & 2032
Figure 54: MEA Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 55: MEA Antibody Drug Conjugates Contract Market Attractiveness Index, By Country – 2022-2032
Figure 56: Asia Pacific Antibody Drug Conjugates Contract Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 57: Asia Pacific Antibody Drug Conjugates Contract Market Absolute $ Opportunity Historical (2017-2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 58: Asia Pacific Antibody Drug Conjugates Contract Market Share, By Condition Type, 2022 & 2032
Figure 59: Asia Pacific Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Condition Type – 2022-2032
Figure 60: Asia Pacific Antibody Drug Conjugates Contract Market Attractiveness Index, By Condition Type – 2022-2032
Figure 61: Asia Pacific Antibody Drug Conjugates Contract Market Share, By Application, 2022 & 2032
Figure 62: Asia Pacific Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Application – 2022-2032
Figure 63: Asia Pacific Antibody Drug Conjugates Contract Market Attractiveness Index, By Application – 2022-2032
Figure 64: Asia Pacific Antibody Drug Conjugates Contract Market Share, By Country, 2022 & 2032
Figure 65: Asia Pacific Antibody Drug Conjugates Contract Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 66: Asia Pacific Antibody Drug Conjugates Contract Market Attractiveness Index, By Country – 2022-2032
Figure 67: US Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 68: US Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 69: US Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 70: Canada Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 71: Canada Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 72: Canada Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 73: Brazil Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 74: Brazil Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 75: Brazil Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 76: Mexico Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 77: Mexico Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 78: Mexico Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 79: Germany Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 80: Germany Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 81: Germany Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 82: U.K. Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 83: U.K. Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 84: U.K. Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 85: France Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 86: France Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 87: France Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 88: Italy Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 89: Italy Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 90: Italy Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 91: Spain Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 92: Spain Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 93: Spain Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 94: Russia Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 95: Russia Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 96: Russia Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 97: China Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 98: China Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 99: China Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 100: Japan Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 101: Japan Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 102: Japan Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 103: South Korea Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 104: South Korea Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 105: South Korea Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 106: India Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 107: India Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 108: India Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 109: South Africa Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 110: South Africa Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 111: South Africa Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 112: Australia Antibody Drug Conjugates Contract Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 113: Australia Antibody Drug Conjugates Contract Market Share, By Condition Type, 2021
Figure 114: Australia Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 115: Saudi Arabia Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 116: UAE Antibody Drug Conjugates Contract Market Share, By Application, 2021
Figure 117: ISRAEL Antibody Drug Conjugates Contract Market Share, By Application, 2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the current worth of the Antibody Drug Conjugates Contract Market?
The Antibody Drug Conjugates Contract Market market is worth US$ 9.2 Billion at present.
What is the growth forecast for Antibody Drug Conjugates Contrac Market?
Value of Antibody Drug Conjugates Contract Market is projected to increase at a CAGR of around 15.5% during 2022 – 2032.
At what rate is the cleavable linker, an application-type segment, is expected to grow between 2022-2032?
The cleavable linker segment is expected to grow with a CAGR of 17.2% during the forecasted period of 2022-2032.
At what % is sales of the Antibody Drug Conjugates Contract Market going to register growth in South Korea?
The South Korean market for Antibody Drug Conjugates Contract is projected to expand at a CAGR of 20% during 2022 – 2032.
What do statistics for the United Kingdom and Japan reveal?
The market in UK is expected to grow at nearly 15.2%, the market in Japan is projected to register a CAGR of nearly 15.5% during 2022 - 2032.
Which segment has a better grip over the market in terms of condition type in the year 2021?
Myeloma has better stats over the market in 2021 and is expected to grow at a CAGR of 17% in the next 10 years.
Antibody Drug Conjugates Contract Market